Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cambria Pharmaceuticals Inc.

Latest From Cambria Pharmaceuticals Inc.

Start-Up Previews (07/2008)

A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Glioblastoma Start-Ups Get Specific," "Glaucoma Start-Ups Reach Critical Mass," and "ALS on the Cusp." Plus these Start-Ups Across Health Care: EarlySense, NeoChord, and Pantec Biosolutions.

ALS on the Cusp

Amyotrophic lateral sclerosis, the devastating neurodegenerative disease, has largely defied R&D efforts, but emerging knowledge, much of it through nonprofit research organizations, raises hopes for better results and treatments with blockbuster potential. In this issue we profile two emerging drug developers hoping to make an impact: Cambria Pharmaceuticals and Knopp Neurosciences.


Cambria Pharmaceuticals Inc.

Although only a small percentage of ALS cases seem tied to the mutant form of SOD1, the deep knowledge about it provides Cambria Pharmaceuticals with a platform for assaying compounds it intends to develop against ALS and other neurodegenerative diseases.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals